Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Several other research firms have also recently weighed in on COLL. Piper Sandler reissued a “neutral” rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright raised Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, July 30th. Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Finally, Truist Financial upped their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $36.09 on Tuesday. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $40.95. The business has a 50-day moving average of $33.50 and a two-hundred day moving average of $34.94. The stock has a market capitalization of $1.18 billion, a P/E ratio of 15.04 and a beta of 0.93. The company has a debt-to-equity ratio of 1.98, a current ratio of 1.21 and a quick ratio of 1.14.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $145.28 million during the quarter, compared to analysts’ expectations of $143.94 million. During the same quarter in the previous year, the firm earned $1.13 earnings per share. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, equities research analysts predict that Collegium Pharmaceutical will post 5.73 EPS for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 56,807 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares in the company, valued at $3,598,549.96. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Institutional Investors Weigh In On Collegium Pharmaceutical

Large investors have recently bought and sold shares of the business. Caxton Associates LP bought a new stake in Collegium Pharmaceutical during the 1st quarter worth approximately $1,730,000. BNP Paribas Financial Markets grew its position in Collegium Pharmaceutical by 119.6% during the 4th quarter. BNP Paribas Financial Markets now owns 146,543 shares of the specialty pharmaceutical company’s stock worth $4,511,000 after acquiring an additional 79,823 shares during the last quarter. SummerHaven Investment Management LLC grew its position in Collegium Pharmaceutical by 1.1% during the 4th quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after acquiring an additional 368 shares during the last quarter. Johnson Investment Counsel Inc. bought a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $257,000. Finally, LSV Asset Management grew its position in Collegium Pharmaceutical by 188.7% during the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after acquiring an additional 248,751 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.